These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9923514)

  • 1. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects.
    Trautmann M; Heinemann M; Zick R; Möricke A; Seidelmann M; Berger D
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):754-60. PubMed ID: 9923514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli.
    Horii T; Kobayashi M; Sato K; Ichiyama S; Ohta M
    J Antimicrob Chemother; 1998 Apr; 41(4):435-42. PubMed ID: 9598774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa.
    Horii T; Ichiyama S; Ohta M; Kobayashi M
    J Med Microbiol; 1999 Mar; 48(3):309-315. PubMed ID: 10334599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Christenson JC; Korgenski EK; Daly JA
    J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F; Quentin C
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics.
    Trautmann M; Zick R; Rukavina T; Cross AS; Marre R
    J Antimicrob Chemother; 1998 Feb; 41(2):163-9. PubMed ID: 9533457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models.
    Tsuji M; Matsuda H; Miwa H; Miyazaki S
    J Antimicrob Chemother; 2003 Feb; 51(2):353-9. PubMed ID: 12562702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.
    Gimeno C; Navarro D; Savall F; Millás E; Farga MA; Garau J; Cisterna R; García-de-Lomas J
    Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):82-5. PubMed ID: 8641311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide.
    Yokochi T; Kusumi A; Kido N; Kato Y; Sugiyama T; Koide N; Jiang GZ; Narita K; Takahashi K
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2410-2. PubMed ID: 8891153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
    Hikida M; Yamazaki Y; Yoshida M; Kawashima K; Nishiki K; Mitsuhashi S
    J Antibiot (Tokyo); 1995 Aug; 48(8):891-2. PubMed ID: 7592037
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
    Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.